Advanced search
Publication Cover
Immunotherapy Volume 16, 2024 - Issue 6
Submit an article Journal homepage
543
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Patterns of Neurological Adverse Events Among a Retrospective Cohort of Patients Receiving Immune Checkpoint Inhibitors

John C Hunting1 Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC27157, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-4066-4763
ORCID Icon,
Andrew T Faucheux2 Department of Hematology & Oncology, Wake Forest School of Medicine, Winston-Salem, NC27157, USA
,
Sarah N Price3 Department of Social Sciences & Health Policy, Wake Forest School of Medicine, Winston-Salem, NC27157, USA
,
Catherine A Elko1 Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC27157, USA
,
Alexander Quattlebaum1 Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC27157, USA
,
Chance Bloomer1 Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC27157, USA
,
Eric Olson2 Department of Hematology & Oncology, Wake Forest School of Medicine, Winston-Salem, NC27157, USA
,
William J Petty2 Department of Hematology & Oncology, Wake Forest School of Medicine, Winston-Salem, NC27157, USA
&
Thomas W Lycan Jr2 Department of Hematology & Oncology, Wake Forest School of Medicine, Winston-Salem, NC27157, USA
 show all
Pages 381-390 | Received 22 Oct 2023, Accepted 20 Dec 2023, Published online: 10 Jan 2024

References

  • Wagner G , StollenwerkHK, KleringsI, PecherstorferM, GartlehnerG, SingerJ. Efficacy and safety of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer (NSCLC): a systematic literature review. OncoImmunology9(1), 1774314 (2020).
  • Fitzsimmons TS , SinghN, WalkerTDJet al. Immune checkpoint inhibitors efficacy across solid cancers and the utility of PD-L1 as a biomarker of response: a systematic review and meta-analysis. Front. Med.10, 1192762 (2023).
  • Haslam A , PrasadV. Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs. JAMA Netw. Open2(5), e192535 (2019).
  • Kwok G , YauTCC, ChiuJW, TseE, KwongY-L. Pembrolizumab (Keytruda). Hum. Vaccines Immunother.12(11), 2777–2789 (2016).
  • Wang Y , ZhouS, YangFet al. Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis. JAMA Oncol.5(7), 1008–1019 (2019).
  • Touat M , TalmasovD, RicardD, PsimarasD. Neurological toxicities associated with immune-checkpoint inhibitors. Curr. Opin. Neurol.30(6), 659–668 (2017).
  • Möhn N , BeutelG, GutzmerR, IvanyiP, SatzgerI, SkripuT. Neurological Immune Related Adverse Events Associated with Nivolumab, Ipilimumab, and Pembrolizumab Therapy-Review of the Literature and Future Outlook. J. Clin. Med.8(11), 1777 (2019).
  • Hsiehchen D , WattersMK, LuR, XieY, GerberDE. Variation in the Assessment of Immune-Related Adverse Event Occurrence, Grade, and Timing in Patients Receiving Immune Checkpoint Inhibitors. JAMA Netw. Open2(9), e1911519 (2019).
  • Mancone S , LycanT, AhmedTet al. Severe neurologic complications of immune checkpoint inhibitors: a single-center review. J. Neurol.265(7), 1636–1642 (2018).
  • Mikami T , LiawB, AsadaMet al. Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database. J. Neurooncol.152(1), 135–144 (2021).
  • Hyun J-W , KimKH, KimS-H, KimHJ. Severe neuromuscular immune-related adverse events of immune checkpoint inhibitors at national cancer center in Korea. J. Cancer Res. Clin. Oncol.149(9), 5583–5589 (2022).
  • Weber JS , HodiFS, WolchokJDet al. Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.35(7), 785–792 (2017).
  • Robert C , SchachterJ, LongGVet al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N. Engl. J. Med.372(26), 2521–2532 (2015).
  • Colevas AD , SetserA. The NCI Common Terminology Criteria for Adverse Events (CTCAE) v 3.0 is the new standard for oncology clinical trials. J. Clin. Oncol.22(Suppl. 14), 6098–6098 (2004).
  • Larkin J , ChmielowskiB, LaoCDet al. Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis. The Oncologist22(6), 709–718 (2017).
  • U.S. Department of Health and Human Services . Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 [Internet]. NIH. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf
  • de Moel EC , RozemanEA, KapiteijnEHet al. Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors. Cancer Immunol. Res.7(1), 6–11 (2019).
  • Yshii LM , GebauerCM, PignoletBet al. CTLA4 blockade elicits paraneoplastic neurological disease in a mouse model. Brain J. Neurol.139(11), 2923–2934 (2016).
  • Forlivesi S , CappellariM, BonettiB. Obesity paradox and stroke: a narrative review. Eat. Weight Disord. – Stud. Anorex. Bulim. Obes.26(2), 417–423 (2021).
  • Simati S , KokkinosA, DalamagaM, ArgyrakopoulouG. Obesity Paradox: Fact or Fiction?Curr. Obes. Rep.12(2), 75–85 (2023).
  • Sheng IY , OrnsteinMC. Ipilimumab and Nivolumab as First-Line Treatment of Patients with Renal Cell Carcinoma: The Evidence to Date. Cancer Manag. Res.12, 4871–4881 (2020).
  • US Food and Drug Administration . US Department of Health and Human Services. FDA orphan drug designations and approvals. Pembrolizumab. ( Internet). www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=381012

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.